Susquehanna International Group, LLP Arbutus Biopharma Corp Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 104,939 shares of ABUS stock, worth $333,706. This represents 0.0% of its overall portfolio holdings.

Number of Shares

104,939

Previous 566,968 81.49%

Holding current value

$333,706

Previous $1.75 Million 76.93%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $4.56 $1.44 Million - $2.11 Million	-462,029 Reduced 81.49%	104,939 $404,000
Q2 2024 Aug 15, 2024	BUY	$2.52 - $3.63 $1.34 Million - $1.93 Million	532,033 Added 1522.92%	566,968 $1.75 Million
Q1 2024 May 07, 2024	SELL	$2.26 - $2.92 $355,149 - $458,866	-157,146 Reduced 81.81%	34,935 $90,000
Q4 2023 Feb 14, 2024	SELL	$1.69 - $2.54 $27,641 - $41,544	-16,356 Reduced 7.85%	192,081 $480,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $195,795 - $233,923	-103,050 Reduced 33.08%	208,437 $423,000
Q2 2023 Aug 11, 2023	BUY	$2.24 - $3.06 $330,606 - $451,631	147,592 Added 90.05%	311,487 $716,000
Q1 2023 May 16, 2023	SELL	$2.23 - $3.1 $291,351 - $405,018	-130,651 Reduced 44.36%	163,895 $496,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $9,519 - $14,204	4,984 Added 1.72%	294,546 $686,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $7,777 - $11,914	4,137 Added 1.45%	289,562 $553,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $307,375 - $492,110	-155,240 Reduced 35.23%	285,425 $774,000
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $184,525 - $303,475	-76,250 Reduced 14.75%	440,665 $1.31 Million
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $453,089 - $671,621	-145,688 Reduced 21.99%	516,915 $2.01 Million
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $1.07 Million - $1.87 Million	404,726 Added 156.95%	662,603 $2.84 Million
Q2 2021 Aug 11, 2021	SELL	$2.5 - $3.51 $1.03 Million - $1.44 Million	-411,234 Reduced 61.46%	257,877 $781,000
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $831,308 - $1.28 Million	264,748 Added 65.47%	669,111 $2.23 Million
Q4 2020 Feb 16, 2021	BUY	$2.76 - $4.97 $564,213 - $1.02 Million	204,425 Added 102.24%	404,363 $1.44 Million
Q3 2020 Nov 16, 2020	BUY	$1.75 - $6.2 $52,552 - $186,186	30,030 Added 17.67%	199,938 $626,000
Q1 2020 May 15, 2020	BUY	$1.01 - $3.42 $106,718 - $361,364	105,662 Added 164.46%	169,908 $172,000
Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $44,600 - $148,155	51,265 Added 394.92%	64,246 $179,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $37,006 - $66,280	-27,617 Reduced 68.03%	12,981 $20,000
Q2 2019 Aug 16, 2019	BUY	$1.46 - $4.44 $3,160 - $9,612	2,165 Added 5.63%	40,598 $84,000
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $28,227 - $85,842	19,334 Added 101.23%	38,433 $80,000
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $15,223 - $26,341	-3,421 Reduced 15.19%	19,099 $96,000
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $76,568 - $157,640	22,520	22,520 $140,000

Others Institutions Holding ABUS

# of Institutions

155

Shares Held

99.5M

Call Options Held

2.31M

Put Options Held

525K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $477M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Arbutus Biopharma Corp Transaction History